683 related articles for article (PubMed ID: 27035235)
21. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
[TBL] [Abstract][Full Text] [Related]
22. TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma.
Shang M; Weng L; Xu G; Wu S; Liu B; Yin X; Mao A; Zou X; Wang Z
J Cell Physiol; 2021 Oct; 236(10):6868-6883. PubMed ID: 33629745
[TBL] [Abstract][Full Text] [Related]
23. Notch1 contributes to chemoresistance to gemcitabine and serves as an unfavorable prognostic indicator in pancreatic cancer.
Du X; Zhao YP; Zhang TP; Zhou L; Chen G; Cui QC; Shi J; Wang TX; You L; Shu H
World J Surg; 2013 Jul; 37(7):1688-94. PubMed ID: 23568245
[TBL] [Abstract][Full Text] [Related]
24. DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine.
Liu F; Gore AJ; Wilson JL; Korc M
PLoS One; 2014; 9(1):e84982. PubMed ID: 24409315
[TBL] [Abstract][Full Text] [Related]
25. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
[TBL] [Abstract][Full Text] [Related]
26. HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1.
Lu Y; Xu D; Peng J; Luo Z; Chen C; Chen Y; Chen H; Zheng M; Yin P; Wang Z
EBioMedicine; 2019 Jun; 44():403-418. PubMed ID: 31103629
[TBL] [Abstract][Full Text] [Related]
27. Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.
Li L; Li Z; Kong X; Xie D; Jia Z; Jiang W; Cui J; Du Y; Wei D; Huang S; Xie K
Gastroenterology; 2014 Aug; 147(2):485-97.e18. PubMed ID: 24859161
[TBL] [Abstract][Full Text] [Related]
28. ECM1 and KRT6A are involved in tumor progression and chemoresistance in the effect of dexamethasone on pancreatic cancer.
Shinomiya Y; Kouchi Y; Harada-Kagitani S; Ishige T; Takano S; Ohtsuka M; Ikeda JI; Kishimoto T
Cancer Sci; 2024 Jun; 115(6):1948-1963. PubMed ID: 38613239
[TBL] [Abstract][Full Text] [Related]
29. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2.
Dangi-Garimella S; Krantz SB; Barron MR; Shields MA; Heiferman MJ; Grippo PJ; Bentrem DJ; Munshi HG
Cancer Res; 2011 Feb; 71(3):1019-28. PubMed ID: 21148071
[TBL] [Abstract][Full Text] [Related]
30. Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer.
Avan A; Quint K; Nicolini F; Funel N; Frampton AE; Maftouh M; Pelliccioni S; Schuurhuis GJ; Peters GJ; Giovannetti E
Curr Pharm Des; 2013; 19(5):940-50. PubMed ID: 22973962
[TBL] [Abstract][Full Text] [Related]
31. Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine resistance in pancreatic ductal adenocarcinoma.
Wang Z; Chen Y; Lin Y; Wang X; Cui X; Zhang Z; Xian G; Qin C
Int J Oncol; 2017 Oct; 51(4):1239-1248. PubMed ID: 28849150
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.
Giovannetti E; Funel N; Peters GJ; Del Chiaro M; Erozenci LA; Vasile E; Leon LG; Pollina LE; Groen A; Falcone A; Danesi R; Campani D; Verheul HM; Boggi U
Cancer Res; 2010 Jun; 70(11):4528-38. PubMed ID: 20460539
[TBL] [Abstract][Full Text] [Related]
33. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM
Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568
[TBL] [Abstract][Full Text] [Related]
34. SNHG14 enhances gemcitabine resistance by sponging miR-101 to stimulate cell autophagy in pancreatic cancer.
Zhang X; Zhao P; Wang C; Xin B
Biochem Biophys Res Commun; 2019 Mar; 510(4):508-514. PubMed ID: 30737032
[TBL] [Abstract][Full Text] [Related]
35. Gemcitabine treatment induces endoplasmic reticular (ER) stress and subsequently upregulates urokinase plasminogen activator (uPA) to block mitochondrial-dependent apoptosis in Panc-1 cancer stem-like cells (CSCs).
Wang L; Zhang Y; Wang W; Zhu Y; Chen Y; Tian B
PLoS One; 2017; 12(8):e0184110. PubMed ID: 28854261
[TBL] [Abstract][Full Text] [Related]
36. Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition.
Kadera BE; Toste PA; Wu N; Li L; Nguyen AH; Dawson DW; Donahue TR
Clin Cancer Res; 2015 Jan; 21(1):157-65. PubMed ID: 25348515
[TBL] [Abstract][Full Text] [Related]
37. Integrin β1 promotes gemcitabine resistance in pancreatic cancer through Cdc42 activation of PI3K p110β signaling.
Yang D; Tang Y; Fu H; Xu J; Hu Z; Zhang Y; Cai Q
Biochem Biophys Res Commun; 2018 Oct; 505(1):215-221. PubMed ID: 30243721
[TBL] [Abstract][Full Text] [Related]
38. LncRNA TUG1 promoted viability and associated with gemcitabine resistant in pancreatic ductal adenocarcinoma.
Yang F; Li X; Zhang L; Cheng L; Li X
J Pharmacol Sci; 2018 Jun; 137(2):116-121. PubMed ID: 29960845
[TBL] [Abstract][Full Text] [Related]
39. BRG1 promotes chemoresistance of pancreatic cancer cells through crosstalking with Akt signalling.
Liu X; Tian X; Wang F; Ma Y; Kornmann M; Yang Y
Eur J Cancer; 2014 Sep; 50(13):2251-62. PubMed ID: 24953335
[TBL] [Abstract][Full Text] [Related]
40. Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance.
Gordon ER; Wright CA; James M; Cooper SJ
BMC Cancer; 2023 Jun; 23(1):524. PubMed ID: 37291514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
